Abstract
Cancer patients benefit from early tumor detection since treatment outcomes are more favorable for less advanced cancers. Platelets are involved in cancer progression and are considered a promising biosource for cancer detection, as they alter their RNA content upon local and systemic cues. We show that tumor-educated platelet (TEP) RNA-based blood tests enable the detection of 18 cancer types. With 99% specificity in asymptomatic controls, thromboSeq correctly detected the presence of cancer in two-thirds of 1,096 blood samples from stage I-IV cancer patients and in half of 352 stage I-III tumors. Symptomatic controls, including inflammatory and cardiovascular diseases, and benign tumors had increased false-positive test results with an average specificity of 78%. Moreover, thromboSeq determined the tumor site of origin in five different tumor types correctly in over 80% of the cancer patients. These results highlight the potential properties of TEP-derived RNA panels to supplement current approaches for blood-based cancer screening.
Original language | English |
---|---|
Pages (from-to) | 999-1009.e6 |
Number of pages | 18 |
Journal | Cancer cell |
Volume | 40 |
Issue number | 9 |
Early online date | 1 Sept 2022 |
DOIs | |
Publication status | Published - 12 Sept 2022 |
Keywords
- Biomarkers, Tumor/genetics
- Blood Platelets
- Early Detection of Cancer/methods
- Humans
- Neoplasms/diagnosis
- RNA
- RNA/genetics
- TEP
- blood
- cancer
- early detection
- liquid biopsy
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
In: Cancer cell, Vol. 40, No. 9, 12.09.2022, p. 999-1009.e6.
Research output: Contribution to journal › Article › Academic › peer-review
TY - JOUR
T1 - Detection and localization of early- and late-stage cancers using platelet RNA
AU - In 't Veld, Sjors G J G
AU - Arkani, Mohammad
AU - Post, Edward
AU - Antunes-Ferreira, Mafalda
AU - D'Ambrosi, Silvia
AU - Vessies, Daan C L
AU - Vermunt, Lisa
AU - Vancura, Adrienne
AU - Muller, Mirte
AU - Niemeijer, Anna-Larissa N
AU - Tannous, Jihane
AU - Meijer, Laura L
AU - Le Large, Tessa Y S
AU - Mantini, Giulia
AU - Wondergem, Niels E
AU - Heinhuis, Kimberley M
AU - van Wilpe, Sandra
AU - Smits, A Josien
AU - Drees, Esther E E
AU - Roos, Eva
AU - Leurs, Cyra E
AU - Tjon Kon Fat, Lee-Ann
AU - van der Lelij, Ewoud J
AU - Dwarshuis, Govert
AU - Kamphuis, Maarten J
AU - Visser, Lisanne E
AU - Harting, Romee
AU - Gregory, Annemijn
AU - Schweiger, Markus W
AU - Wedekind, Laurine E
AU - Ramaker, Jip
AU - Zwaan, Kenn
AU - Verschueren, Heleen
AU - Bahce, Idris
AU - de Langen, Adrianus J
AU - Smit, Egbert F
AU - van den Heuvel, Michel M
AU - Hartemink, Koen J
AU - Kuijpers, Marijke J E
AU - Oude Egbrink, Mirjam G A
AU - Griffioen, Arjan W
AU - Rossel, Rafael
AU - Hiltermann, T Jeroen N
AU - Lee-Lewandrowski, Elizabeth
AU - Lewandrowski, Kent B
AU - De Witt Hamer, Philip C
AU - Kouwenhoven, Mathilde
AU - Reijneveld, Jaap C
AU - Leenders, William P J
AU - Hoeben, Ann
AU - Verdonck-de Leeuw, Irma M
AU - Leemans, C René
AU - Baatenburg de Jong, Robert J
AU - Terhaard, Chris H J
AU - Takes, Robert P
AU - Langendijk, Johannes A
AU - de Jager, Saskia C
AU - Kraaijeveld, Adriaan O
AU - Pasterkamp, Gerard
AU - Smits, Minke
AU - Schalken, Jack A
AU - Łapińska-Szumczyk, Sylwia
AU - Łojkowska, Anna
AU - Żaczek, Anna J
AU - Lokhorst, Henk
AU - van de Donk, Niels W C J
AU - Nijhof, Inger
AU - Prins, Henk-Jan
AU - Zijlstra, Josée M
AU - Idema, Sander
AU - Baayen, Johannes C
AU - Teunissen, Charlotte E
AU - Killestein, Joep
AU - Besselink, Marc G
AU - Brammen, Lindsay
AU - Bachleitner-Hofmann, Thomas
AU - Mateen, Farrah
AU - Plukker, John T M
AU - Heger, Michal
AU - de Mast, Quirijn
AU - Lisman, Ton
AU - Pegtel, D Michiel
AU - Bogaard, Harm-Jan
AU - Jassem, Jacek
AU - Supernat, Anna
AU - Mehra, Niven
AU - Gerritsen, Winald
AU - de Kroon, Cornelis D
AU - Lok, Christianne A R
AU - Piek, Jurgen M J
AU - Steeghs, Neeltje
AU - van Houdt, Winan J
AU - Brakenhoff, Ruud H
AU - Sonke, Gabe S
AU - Verheul, Henk M
AU - Giovannetti, Elisa
AU - Kazemier, Geert
AU - Sabrkhany, Siamack
AU - Schuuring, Ed
AU - Sistermans, Erik A
AU - Wolthuis, Rob
AU - Meijers-Heijboer, Hanne
AU - Dorsman, Josephine
AU - Oudejans, Cees
AU - Ylstra, Bauke
AU - Westerman, Bart A
AU - van den Broek, Daan
AU - Koppers-Lalic, Danijela
AU - Wesseling, Pieter
AU - Nilsson, R Jonas A
AU - Vandertop, W Peter
AU - Noske, David P
AU - Tannous, Bakhos A
AU - Sol, Nik
AU - Best, Myron G
AU - Wurdinger, Thomas
N1 - Copyright © 2022 The Author(s). Published by Elsevier Inc. All rights reserved.
PY - 2022/9/12
Y1 - 2022/9/12
N2 - Cancer patients benefit from early tumor detection since treatment outcomes are more favorable for less advanced cancers. Platelets are involved in cancer progression and are considered a promising biosource for cancer detection, as they alter their RNA content upon local and systemic cues. We show that tumor-educated platelet (TEP) RNA-based blood tests enable the detection of 18 cancer types. With 99% specificity in asymptomatic controls, thromboSeq correctly detected the presence of cancer in two-thirds of 1,096 blood samples from stage I-IV cancer patients and in half of 352 stage I-III tumors. Symptomatic controls, including inflammatory and cardiovascular diseases, and benign tumors had increased false-positive test results with an average specificity of 78%. Moreover, thromboSeq determined the tumor site of origin in five different tumor types correctly in over 80% of the cancer patients. These results highlight the potential properties of TEP-derived RNA panels to supplement current approaches for blood-based cancer screening.
AB - Cancer patients benefit from early tumor detection since treatment outcomes are more favorable for less advanced cancers. Platelets are involved in cancer progression and are considered a promising biosource for cancer detection, as they alter their RNA content upon local and systemic cues. We show that tumor-educated platelet (TEP) RNA-based blood tests enable the detection of 18 cancer types. With 99% specificity in asymptomatic controls, thromboSeq correctly detected the presence of cancer in two-thirds of 1,096 blood samples from stage I-IV cancer patients and in half of 352 stage I-III tumors. Symptomatic controls, including inflammatory and cardiovascular diseases, and benign tumors had increased false-positive test results with an average specificity of 78%. Moreover, thromboSeq determined the tumor site of origin in five different tumor types correctly in over 80% of the cancer patients. These results highlight the potential properties of TEP-derived RNA panels to supplement current approaches for blood-based cancer screening.
KW - Biomarkers, Tumor/genetics
KW - Blood Platelets
KW - Early Detection of Cancer/methods
KW - Humans
KW - Neoplasms/diagnosis
KW - RNA
KW - RNA/genetics
KW - TEP
KW - blood
KW - cancer
KW - early detection
KW - liquid biopsy
UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85137385164&origin=inward
UR - https://www.ncbi.nlm.nih.gov/pubmed/36055228
UR - http://www.scopus.com/inward/record.url?scp=85137385164&partnerID=8YFLogxK
U2 - 10.1016/j.ccell.2022.08.006
DO - 10.1016/j.ccell.2022.08.006
M3 - Article
C2 - 36055228
SN - 1535-6108
VL - 40
SP - 999-1009.e6
JO - Cancer cell
JF - Cancer cell
IS - 9
ER -